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Introduction: PPARg is an essential regulator of lipid, glucose, and insulin
metabolism. PPARg full agonists, such as thiazolidinediones, are the mainstay
drugs for the treatment of type 2 diabetes; however, undesirable clinical side
15effects have contributed to poor compliance with therapy and limited their
full therapeutic potential. In the last few years, many efforts have been
made in the discovery and development of selective PPARg modulators
(SPPARgMs) as safer alternatives to PPARg full agonists.
Areas covered: This application claims the plant-derived amorfrutins or their
20synthetic analogs as SPPARgMs with potential to exhibit glucose-lowering
effects without provoking side effects associated with full PPARg activation.
Specifically, the in vivo glucose-lowering properties of the high-affinity
SPPARgM amorfrutin B are described. Moreover, examples of this class of
compounds exhibit interesting antiproliferative activities.
25Expert opinion: The patent (WO2014177593 A1) under discussion proposes
enriching functional food products or phytomedical extracts with safe licorice
extracts, containing sufficient amounts of amorfrutins, with the ultimate goal
of inhibiting the early development of disorders such as insulin resistance.
Interestingly, some example compounds show anticancer properties in colon,
30prostate, and breast malignancies. However, further in vivo investigations of
the claimed compounds for these specific indications will be necessary to
definitively support their clinical applications.
Keywords: anticancer, diabetes, insulin resistance, natural product, peroxisome
35proliferator-activated receptor, selective PPARg modulators
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1. Introduction
Peroxisome proliferator-activated receptors (PPARs) belong to the II class of nuclear
receptors superfamily. They are ligand-dependent transcriptional factors involved in
40the control and expression of several genes implicated in glucidic and lipidic homeo-
stasis and energetic balance. PPARs are lipid sensors activated by specific natural
and synthetic ligands, which play an important role during cell signaling [1]. PPARs
dynamically shuttle between nucleus and cytoplasm, although they constitutively
and predominantly appear in nucleus [2]. The nuclear-cytoplasmic shuttling of
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45 PPARs is regulated by respective PPAR ligands [2]. In
unstimulated cells, PPARs are located in the cytoplasm as het-
erodimers complexed to their repressors. After ligation with
their agonists, PPARs heterodimerize with retinoid X receptor
(RXR) and co-activators such as p300 are recruited [3,4]; this
50 complex is translocated to the nucleus where it recognizes
specific DNA sequence elements termed as peroxisome prolif-
erator response element (PPRE) in promoters of target genes
(Figure 1). The transcriptional activity of PPARs is finely
regulated by co-activators or co-repressors, which modulate
55 signaling and interaction with the basal transcription
machinery [4]. In the absence of ligands (ligand-independent
repression), the PPAR/RXR complex is bound to transcrip-
tional co-repressors and histone deacetylases, which prevents
its binding to PPRE [5]. Upon ligand activation (ligand-
60 dependent transactivation), PPARs undergo conformational
change, and recruit co-activators such as p300/CBP and
p160 to displace co-repressors, resulting in binding of target
gene PPRE and inducing transcription.
To date, three human PPAR isoforms have been identified:
65 PPARa, PPARb/d (also known as PPARb or PPARd),
and PPARg . Each isoform has a distinct tissue distribution,
different activating ligands, and selective function in the regu-
lation of metabolic processes in the organism (Table 1) [6-8].
PPARg is the target of thiazolidinediones (TZD) class of
70insulin-sensitizing drugs, clinically employed in patients
with type 2 diabetes [9]. However, these PPARg activators
have undesirable clinical side effects such as weight gain,
peripheral edema, bone loss, increased risk of congestive
heart failure, and other disorders that contribute to a poor
75compliance with therapy in diabetic patients.
Selective PPARg modulators (SPPARgMs) are novel
PPARg ligands that can promote a differential cofactor
recruitment profile, leading to specific patterns of gene
expression. In preclinical species, SPPARgMs were shown to
80retain antidiabetic efficacy comparable to that of full PPARg
agonists while displaying reduced PPARg mechanism-based
adverse effects [10]. Thus, the use of SPPARgMs is a promising
approach for developing glucose-lowering agents with an
acceptable safety profile [11].
85The patent application [12], from Max-Planck Institute and
Boyce Thompson Institute For Plant Research, that is the
subject of this evaluation, specifically claims that the amorfru-
tins, a family of phenyl terpenoid natural products isolated
from the edible parts of the legumes Glycyrrhiza foetida and
90Amorpha fruticosa, selectively modulate PPARg activity at
low nanomolar concentrations, offering a promising approach
to prevent or treat complex metabolic diseases such as insulin
resistance or type 2 diabetes.
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Figure 1. Transcriptional Regulation by PPARs. After ligand binding, PPARs undergo conformational changes, which lead to
recruitment of RXR and coactivators. The resultant heterodimers bind to specific DNA response elements called PPREs, causing
target gene transcription (ligand-dependent transactivation). In the absence of ligands, PPARs bind the promoters of their
target genes and repress transcription by recruiting the co-repressor complex (ligand-independent transrepression).
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2. Chemistry
95 Amorfrutins and their synthetic analogs claimed in this patent
were isolated from 20 microbial strains (of terrestrial and
marine origin) and different plants or obtained by chemical
synthesis. Compound isolation was carried out by extracting
twice dried seeds, roots, aerial parts of plants or fungal strains
100 with methanol/methyl-tert-butyl ether (MTBE) or methanol/
acetone. By repeated chromatography (stationary phase
RP-8 and RP-18, mobile phase methanol-water, and acetoni-
trile-water), natural products were isolated in a purity
of > 70%. Structures were elucidated by interpretation of
105 LCMS, 1D and 2D NMR (HSQC, HMBC, HH-COSY)
data.
The 43 compounds described in the document are struc-
turally simplified by the benzene ring (I) (Figure 2), wherein
R1--R6 represent simple or more complex aliphatic or aro-
110 matics groups described in detail in the patent application.
A variant to the core scaffold benzene ring is that R2 together
with R3 or R3 together with R4 form with the two carbons of
the benzene ring to which they are attached 2,3-dihydrofuran
or furane rings (II) substituted with saturated or unsaturated,
115 linear or branched R7 alkyl groups (Figure 2).
The structures of the most interesting novel amorfrutins
disclosed are reported in Figure 2. Amorfrutins of general for-
mula 10,11,12 disclosed in the invention can be efficiently
synthesized by three steps starting from the ketone 3 and the
120 malonate derivative 4 (Figure 3).
To access ketone 3, hydrazone 5, obtained from the corre-
sponding methyl ketone, is reacted with commercially avail-
able brominated derivative 6 in the presence of a strong base
such as lithium diisopropylamide in anhydrous THF. Exam-
125 ples of suitable brominated derivative 6 are 1-bromo-3-meth-
ylbut-2-ene and (2Z)-1-bromo-3,7-dimethylocta-2,6-diene.
After treatment of diethyl malonate 8 with Mg turnings in
absolute ethanol and a catalytic amount of CCl4, the interme-
diate magnesium salt is reacted with acyl chloride 7 to provide
130 enol 9. Suitable acyl chlorides 7 are hydrocinnamoyl chloride,
pentanoyl chloride, butanoyl chloride, propanoyl chloride,
ethanoyl chloride, and formyl chloride. Enol 9 is converted
to corresponding chloride 4 by treatment with phosphoryl
chloride (POCl3) and triethylamine (Et3N).
135Subsequent treatment of chloride 4 with ketone 3 provides
amorfrutin analog 10 that can be further methylated to pro-
vide the analog 11. Cleavage of the methyl ester on methyl-
ated analog 11 furnishes amorfrutin 12.
3. Biology and action
140The compounds described in this patent were evaluated
in vitro by binding and cofactor recruitment assays and by
transcriptional activation assays in primary human adipocytes
and murine preosteoblasts, as well as in vivo using insulin-
resistant high-fat-diet-fed C57BL/6 mice. Table 2 summarizes
145the binding and activation of PPARs by the most interesting
amorfrutins disclosed in the patent.
Among the various compounds tested, amorfrutin B
emerged as the most selective and potent SPPARgM. Amor-
frutin B had the lowest, nanomolar, binding affinity constant
150(Ki) to purified PPARg (Ki = 0.02 µM; Table 2) similar to the
standard PPARg-targeting drug rosiglitazone (RGZ)
(Ki = 0.007 µM), and 12 times lower than amorfrutin
1 (Ki = 0.24 µM). This compound activated chimeric
Gal4-PPARg-dependent reporter gene expression as partial
155agonist (with EC50 = 0.07 µM and maximal efficacy 4-fold
lower than RGZ). Amorfrutins 1 -- 4 also were able to bind
to purified PPARg (Table 2) and to activate chimeric
Gal4-PPARg-dependent reporter gene expression as partial
agonists, although less potently than amorfrutin B. In addi-
160tion, both amorfrutins 1 -- 4 and amorfrutin B bound to the
subtypes PPARa (which are mainly expressed in the liver)
and PPARb/d (which are ubiquitously expressed), with amor-
frutin B exhibiting lower micromolar Ki values (Ki = 2.6 and
1.8 µM for PPARa and PPARb/d, respectively).
165The inventors of this patent also investigated the potential
transcriptional activation of these compounds using reporter
gene assays. All compounds showed PPARg activation, with
EC50 values ranging from 25 nM to 6.9 µM and transactiva-
tion efficacies ranging from 5 to 79% relative to RGZ. Once
170more, amorfrutin B diplayed nanomolar effective concentra-
tions (EC50 = 0.07 µM) and reduced maximal PPARg
Table 1. Ligands, tissue distribution, and main biological effects of PPARs.
Receptor Ligand Tissue distribution Function
PPARa FA, fibrates, Eicosanoids Heart, liver, kidney, adipose tissue,
skeletal muscle
FA catabolism, lipid homeostasis,
anti-inflammatory
PPARg PUFAs, 15d-PGJ2, TZD Adipose tissue, macrophages, kidney
pancreas, spleen colon and large
intestine, heart, skeletal muscle
Glucose homeostasis, insulin homeostasis,
adipocyte differentiation, macrophage
function, anti-proliferating, anti-angiogenic
PPARb/d FA, L-165041, GW0742,
GW501516
Ubiquitous, highly expressed in skin,
brain and adipose tissue
FA catabolism, glucose homeostasis,
adipocyte differentiation, anti-inflammatory,
carcinogenesis (?)
15d-PGJ2: 15-deoxy-delta-12,14-prostaglandin J2; FA: Fatty acids; PUFAs: Polyunsaturated FA; TZD: Thiazolidinediones.
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III
Figure 2. Structures of the most interesting amorfrutins described in the patent application.
(5) (6) (3)
(4)(9)(8)
(10)
(4) (3)
(11) (12)
(7)
Figure 3. General synthetic route utilized to prepare the amorfrutins with general formula (10), (11), and (12) disclosed in this
patent. (a) LDA, THF. (b) Mg turnings, EtOH, CCl4. (c) POCl3, Et3N. (d) LDA, THF. (e) Iodomethane (MeI), NaHCO3. (f) KOH,
DMSO.
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activation (efficacy = 25%). In contrast to the full PPARg
agonist RGZ, amorfrutins only partially induced transcrip-
tional activation of PPARg , suggesting that the compounds
175 of this invention represent a new chemical class of
SPPARgMs. Transcriptional activation of the PPARa sub-
type was additionally tested in the same reporter gene assay,
with amorfrutin B exhibiting EC50 and efficacy values of
0.91 µM and 61%, respectively. Amorfrutins 1 -- 4 showed
180 EC50 and efficacy values ranging from 0.39 to 0.81 µM and
13 to 23%, respectively. Finally, amorfrutin B provoked
the activation of the PPARb/d subtype at nanomolar concen-
trations (EC50 = 0.74 µM), although the efficacy of this
activation was only 3%.
185 Interestingly, amorfrutin B induced partial recruitment of
several PPARg transcriptional coactivators and reduced bind-
ing of the corepressor nuclear receptor 1 with an IC50 value
similar to RGZ (60 vs 23 nM with RGZ), but with lower
maximal dissociation efficacy (61 vs 100% RGZ, Table 2).
190 Using a PPARg activation assay, it was shown that
amorfrutin B regulated gene expression in human adipocytes
in a PPARg-dependent manner, thus suggesting potential
glucose-lowering effects with, presumably, lower susceptibility
to adipose-derived body weight gain in vivo upon amorfrutin
195 B treatment. Previous work has shown that phosphorylation
of PPARg at Ser273 by cyclin-dependent kinase 5 stimulates
diabetogenic gene expression in adipose tissues [13]. Inhibition
of this modification is a key therapeutic mechanism for anti-
diabetic drugs that bind PPARg , such as TZDs and PPARg
200 partial agonists or non-agonists [13]. The inventors showed
that amorfrutin 1 blocked the phosphorylation of PPARg in
visceral white adipose tissue of DIO mice [14], whereas
amorfrutin B did not produce any significant change at this
phosphorylation site [15]. In insulin-resistant, diet-induced
205 obese and in genetic diabetes mouse models, treatment with
100 mg/kg/d of amorfrutin B strongly increased insulin
sensitivity and glucose tolerance and improved many other
physiological parameters [14,15]. Strikingly, early intervention
with amorfrutin B inhibited the development of fatty liver
210during high-fat diet treatment of mice, an exciting feature to
prevent metabolic liver diseases. In various diabetic mouse
models, amorfrutin B did not show the unwanted side effects
of the TZDs, such as weight gain or adverse effects on
osteoblastogenesis and fluid retention.
215Further, some amorfrutins disclosed in the patent applica-
tion revealed concentration-dependent antiproliferative effects
against HT-29 colon, PC3 prostate, and MCF-7 breast cancer
cells with IC50 values ranging from 8.1 to 57.3 µM and with
efficacies of up to 100% cancer cell death induction. One of
220the example compounds (NP-015934) was co-administered
with cisplatin or irinotecan, showing additive effects on inhib-
iting HT-29 cell proliferation. The inventors suggested the
involvement of apoptosis as a mechanism of compound-
induced cancer cell owing to considerable caspase activation
225in all tested cancer cells, striking DNA fragmentation,
substantial phosphatidylserine externalization, significant for-
mation of reactive oxygen species, and loss of mitochondrial
transmembrane potential.
4. Expert opinion
230Given worldwide increases in the incidence of obesity and
type 2 diabetes, new strategies for preventing and treating
metabolic diseases are needed. Therefore, it is not surprising
that this field attracts increasing attention of academic and
pharmaceutical research to investigate potential exploitation
235as drug targets and/or new types of drugs.
The present patent represents a logical evolution of
the work previously realized by the same inventors [14,15].
The compounds disclosed represent a family of structurally
new and powerful natural antidiabetics, the amorfrutins,
240which are high-affinity SPPARgMs with potential to exhibit
strong glucose-lowering properties without provoking side
Table 2. Binding, activation, and cofactor recruitment of PPARs by amorfrutins.
Receptor Amorfrutin 1 Amorfrutin 2 Amorfrutin 3 Amorfrutin 4 Amorfrutin B RGZ
PPARa
Ki (µM) 27 25 115 8.0 2.6 n.d.
EC50 (µM) 0.70 0.39 0.81 0.66 0.91 n.d.
Efficacy (%) 23 18 13 14 61 n.d.
PPARb/d
Ki (µM) 27 17 68 6.0 1.8 n.d.
EC50 (µM) 0.74 n.d.
Efficacy (%) 3 n.d.
PPARg
Ki (µM) 0.24 0.29 0.35 0.28 0.02 0.007
EC50 (µM) 0.46 1.20 4.50 0.98 0.07 0.004
Efficacy (%) 39 30 22 15 25 100
NCoR
EC50/IC50 (nM) 51 32 2.8 34 60 23
Efficacy (%) 75 85 92 78 61 100
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effects associated with full PPARg activation. In addition to
amorfrutins, many other natural products have been found
to act as SPPARgMs, partial, or dual agonists [16]. In particu-
245 lar, honokiol, magnolol, resveratrol and amorphastilbol have
shown the same efficacy of amorfrutins in improving blood
glucose levels and other relevant parameters in diabetic ani-
mals with few side effects compared with TZD treatments.
Additionally, preclinical and Phase I/II clinical studies with
250 synthetic SPPARgMs, INT131 [17], MBX-102 [18],
MB-2044 [19], balaglitazone [20], and indeglitazar [21] have
provided evidence of comparable or better insulin sensitiza-
tion with respect to full agonist without PPARg-mediated
side effects. An analysis of published documents by Espacenet
255 revealed that SPPARgMs as safer alternatives to PPARg full
agonists seem to represent yet a middlingly competitive field,
which is so far mainly investigated by academia or industry
with at least 78 published documents.
The invention claimed in this patent may be directed to
260 enrich functional food products or phytomedical extracts
with safe licorice extracts, containing sufficient amounts of
amorfrutins, with the ultimate goal of inhibiting the early
development of disorders such as insulin resistance. The cen-
tral core of the compounds described in this patent is identical
265 to that previously disclosed by these inventors [14,15], whereas a
number of modifications are proposed to external
“appendages”. In addition, in vitro and in vivo glucose-
lowering activities of only one example molecule,
amorfrutin B, are described, although the synthetic scheme
270 utilized to reach these compounds is well characterized
and amenable to a more thorough exploration of the
structure--activity relationships for this class of compounds.
Pharmacokinetic studies in C57BL/6 mice demonstrated
good absorption of amorfrutin B after oral dosing of
275 100 mg/kg (Cmax = 30.4 mg/l; Cmin = 0.015 mg/l;
AUC = 85.4 mg/l  h) and a relatively long half-life
(t1/2 = 2.3 h; ke = 0.307 h
-1; CL = 30.0 ml/h). Thus, the
animal studies discussed, although quite promising and
suggestive of an antidiabetic effect of amorfrutin B, need to
280 be expanded to primates and then humans before more
definitive conclusions can be drawn. Moreover, the authors
did not report the in vivo experiments for the remaining
example molecules, nor did the authors perform extensive
carcinogenicity tests (2 y/two species), a Food and Drug
285Administration requirement for long-term studies in humans.
Hence, although amorfrutins appear promising, it is impossi-
ble at present to predict whether they will have a better safety
profile in humans than TZDs.
The novelty of the patent resides in the additional antipro-
290liferative and pro-apoptotic properties of PPARg-binding nat-
ural amorfrutins. Eight example molecules were demonstrated
to suppress the growth of HT-29, PC3, and MCF-7 cancer
cells, by inducing caspase-associated apoptosis via the mito-
chondrial pathway. However, the therapeutic claims for the
295treatment of many types of cancer are not supported by direct
studies on the example compounds. Ample evidence in the
literature supports PPARg involvement in modulation of
proliferation and apoptosis of many cancer cell types and its
expression in many human tumors including lung, breast,
300colon, prostate, and bladder cancer [22-24]; however, the exact
mechanisms underlying these effects are still being explored.
In particular, it remains to be further explored whether
activation of PPARg itself or PPARg-independent effects of
amorfrutins contribute to the inhibition of cancer cell growth.
305Thus, further in vitro and in vivo investigations of the claimed
compounds for these specific indications will be necessary to
definitively support their clinical applications.
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